This site is intended for health professionals only

COPD exacerbations predictable with CT biomarker model

Using a CT biomarker model researchers have been able to predict disease exacerbations in patients with chronic obstructive pulmonary disease

Using a CT biomarker based model, US researchers have been able to predict disease exacerbations in patients with chronic obstructive pulmonary disease (COPD).

Chronic obstructive pulmonary disease is associated with a high level of morbidity, disability and mortality, affecting around 10.3% of the world’s population aged between 30 and 79. The condition is associated with disease exacerbations which contribute to a decline in lung function over time and often result in hospitalisation. In recent years, computed tomography (CT) has been used to identify the phenotypic abnormalities in COPD that can be seen and quantitatively evaluated such as airway wall thickening which contributes to airflow limitations. Despite the potential value of CT-derived measures, using predictive models using these measures has not been explored. In the current study, the US team hypothesised that a CT biomarker model that included measures such as parenchymal texture and airway wall thickness could be used to predict disease exacerbations. They retrospectively examined patient data obtained from the SIROMICS cohort study, which sought to better understand COPD exacerbations. The team used 3-year follow-up data to develop their models for predicting exacerbations and which together CT-based measure of density gradient texture and airway structure also included several variables such as age, gender, exacerbation history. The performance of the model was assessed using the receiver operating characteristics curve (AUC) and compared to models based on exacerbation history and the exercise capacity (BODE) index.

CT biomarker model prediction of exacerbations

A total of 1956 participants with a mean age of 63.1 years (52%) completed the 3-year follow-up and were included in the analysis.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in clinical care at events delivered by renowned experts from CofE

The CT biomarker model had an AUC of 0.854 for prediction of at least one severe exacerbation within 3 years and 0.93 for consistent exacerbations (defined as at least one acute episode in each of the three years. This was higher than models based on either exacerbation history (AUC = 0.823) or using the BODE index (AUC = 0.812).

In a further analysis using an external cohort of nearly 7,000 participants, the CT biomarker model had an AUC of 0.768 for at least one severe exacerbation.

The authors suggested that CT biomarker models could in the future, potentially be used to investigate the underlying disease mechanisms that lead to an exacerbation.

Chaudhary MFA et al. Predicting severe chronic obstructive pulmonary disease exacerbations using quantitative CT: a retrospective model development and external validation study. Lancet Digit Health 2023

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine